Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Verastem, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06682572CT.gov A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | — | Active Not Recruiting | — | — | — |
NCT06394804CT.gov A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | — | Recruiting | — | — | — |
NCT06072781CT.gov A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | — | Recruiting | — | — | — |
NCT05512208CT.gov A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | — | Recruiting | — | — | — |
NCT04625270CT.gov A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | — | Active Not Recruiting | — | — | — |
NCT03875820CT.gov Phase I Trial of Defactinib and VS-6766. | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avutometinib (this asset) | Verastem, Inc. | P3 | BB · 68 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Nogitecan | National Cancer Institute (NCI) | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2/3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Avutometinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P2 | B · 60 |
| Endometrioid Adenocarcinoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avutometinib in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/avutometinib-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →